Estradiol Suppression for the Treatment of Metastatic Breast Cancer in Premenopausal Women
Trial ID or NCT#
NCT00186121
Status
NOT RECRUITING
Purpose
To evaluate the antitumor activity, toxicity, and effectiveness of the combination of goserelin (Zoladex) and anastrozole (Arimidex) in the treatment of premenopausal women with hormone receptor positive metastatic carcinoma of the breast.
Official Title
A Phase II Trial of Arimidex Plus Zoladex in the Treatment of Hormone Receptor Positive, Metastatic Carcinoma of the Breast in Premenopausal Women
Eligibility Criteria
Ages Eligible for Study: 18 Years to 70 Years
Sexes Eligible for Study: FEMALE
Accepts Healthy Volunteers: No
Exclusion Criteria:
Investigator(s)
Contact us to find out if this trial is right for you.
Contact
Mary Chen
6507238686
View on ClinicalTrials.gov
